
Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0271807
document
INTRODUCTION: The aim of this study was to determine the efficacy of early tocilizumab treatment for hospitalized patients with COVID-19 disease. METHODS: Open-label randomized phase II clinical trial investigating tocilizumab in patients with proven COVID-19 admitted to the general ward and in need of supplemental oxygen. The primary endpoint of the study was 30-day mortality with a prespecified 2-sided significance level of α = 0.10. A post-hoc analysis was performed for a combined endpoint of mechanical ventilation or death at 30 days. Secondary objectives included comparing the duration...
Abraham Rutgers, Peter E Westerweel, Bronno van der Holt, Simone Postma, Marit G A van Vonderen, Djura P Piersma, Douwe Postma, Maarten van den Berge, Eefje Jong, Marten de Vries, Leonie van der Burg, Dennis Huugen, Marjolein van der Poel, Linda M Kampschreur, Marcel Nijland, Jaap H Strijbos, Menno Tamminga, Pim G N J Mutsaers, Suzanne Schol-Gelok, Margriet Dijkstra-TiekstraGrigory Sidorenkov, Julien Vincenten, Wouter H van Geffen, Marjolein Knoester, Jos Kosterink, Reinold Gans, Coen Stegeman, Gerwin Huls, Tom van Meerten
Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0267543
document
BACKGROUND AND PURPOSE: PARP inhibitors have been shown to increase the efficacy of radiotherapy in preclinical models. Radioimmunotherapy results in selective radiation cytotoxicity of targeted tumour cells. Here we investigate the combined effect of anti-CD37 β-emitting 177Lu-NNV003 radioimmunotherapy and the PARP inhibitor olaparib, and gene expression profiles in CD37 positive non-Hodgkin’s lymphoma cell lines. MATERIALS AND METHODS: The combined effect of 177Lu-NNV003 and olaparib was studied in seven cell lines using a fixed-ratio ray design, and combination index was calculated for each combination concentration. mRNA was extracted before...
Marion M Malenge, Astri Fjelde Maaland, Ada Repetto-Llamazares, Brian Middleton, Marcel Nijland, Lydia Visser, Sebastian Patzke, Helen Heyerdahl, Arne Kolstad, Trond Stokke, Anne Hansen Ree, Jostein Dahle
Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach
Published in: Cancers
Access to document
10.3390/cancers14081857
document
Simple Summary This review summarizes gene-expression profiling insights into the background and origination of diffuse large B-cell lymphomas (DLBCL). To further unravel the molecular biology of these lymphomas, a consortium panel called BLYM-777 was designed including genes important for subtype classifications, genetic pathways, tumor-microenvironment, immune response and resistance to targeted therapies. This review proposes to combine this transcriptomic method with genomics, proteomics, and patient characteristics to facilitate diagnostic classification, prognostication, and the development of new targeted therapeutic strategies in DLBCL. Gene-expression profiling (GEP) is used to study the...
Fleur A de Groot, Ruben A L de Groen, Anke van den Berg, Patty M Jansen, King H Lam, Pim G N J Mutsaers, Carel J M van Noesel, Martine E D Chamuleau, Wendy B C Stevens, Jessica R Plaça, Rogier Mous, Marie José Kersten, Marjolein M W van der Poel, Thomas Tousseyn, F J Sherida H Woei-A-Jin, Arjan Diepstra, Marcel Nijland, Joost S P Vermaat
Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma
Published in: Cancers
Access to document
10.3390/cancers14051346
document
Multiple gene expression profiles have been identified in diffuse large B-cell lymphoma (DLBCL). Besides the cell of origin (COO) classifier, no signatures have been reproduced in independent studies or evaluated for capturing distinct aspects of DLBCL biology. We reproduced 4 signatures in 175 samples of the HOVON-84 trial on a panel of 117 genes using the NanoString platform. The four gene signatures capture the COO, MYC activity, B-cell receptor signaling, oxidative phosphorylation, and immune response. Performance of our classification algorithms were confirmed in the original datasets. We were...
Jessica Rodrigues Plaça, Arjan Diepstra, Tjitske Los, Matías Mendeville, Annika Seitz, Pieternella J Lugtenburg, Josée Zijlstra, King Lam, Wilson Araújo da Silva, Bauke Ylstra, Daphne de Jong, Anke van den Berg, Marcel Nijland
Successful treatment of hairy cell leukemia variant with obinutuzumab
Published in: Annals of Hematology
Access to document
10.1007/s00277-021-04559-z
document
Diana Al-Sarayfi, Freek O. Meeuwes, Thijs Oude Munnink, Wouter Plattel, Stefano Rosati, Estella Matutes, Marcel Nijland